AI English summary of an SEC filing — figures as filed
The company said its officers will speak with investors over the next several weeks and intend to reaffirm its 2024 full-year net income outlook of greater than $34.05 per diluted share. The outlook includes about $3.15 per diluted share of net unfavorable items.
Key points
AI summaryThe company said its officers will speak with investors over the next several weeks and intend to reaffirm its 2024 full-year net income outlook of greater than $34.05 per diluted share. The outlook includes about $3.15 per diluted share of net unfavorable items.
The company said it continues to expect adjusted net income, which excludes net unfavorable items, to be greater than $37.20 per diluted share.
The company said the outlook does not include any adjustment items beyond those reported in its Q1 2024 earnings release.
The company said the information furnished under Item 7.01 is not deemed "filed" for purposes of Section 18 of the 1934 Securities Exchange Act and, unless expressly set forth by specific reference, is not incorporated by reference in any filing under the 1933 Securities Act.
Summary
AI-writtenAnalysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Elevance Health Reaffirms 2024 Full-Year Net Income Outlook
The company said its officers will speak with investors over the next several weeks and intend to reaffirm its 2024 full-year net income outlook of greater than $34.05 per diluted share. The outlook includes about $3.15 per diluted share of net unfavorable items.
Source · Based on the filing body and exhibits
Adjusted Net Income Outlook Greater Than $37.20 Per Share
The company said it continues to expect adjusted net income, which excludes net unfavorable items, to be greater than $37.20 per diluted share.
Source · Based on the filing body and exhibits
Adjustment Items Included in Outlook
The company said the outlook does not include any adjustment items beyond those reported in its Q1 2024 earnings release.
Source · Based on the filing body and exhibits
Filing Status of Information Under Item 7.01
The company said the information furnished under Item 7.01 is not deemed "filed" for purposes of Section 18 of the 1934 Securities Exchange Act and, unless expressly set forth by specific reference, is not incorporated by reference in any filing under the 1933 Securities Act.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…